PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 161 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is 0.48 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $55,000 | -49.1% | 14,421 | -44.2% | 0.01% | -42.1% |
| Q4 2018 | $108,000 | -25.0% | 25,867 | +55.9% | 0.02% | -51.3% |
| Q4 2016 | $144,000 | +17.1% | 16,596 | -41.5% | 0.04% | +18.2% |
| Q1 2016 | $123,000 | -10.9% | 28,359 | +53.3% | 0.03% | -31.2% |
| Q2 2015 | $138,000 | – | 18,500 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 1,583,925 | $8,007,000 | 1.48% |
| Phocas Financial Corp. | 1,022,708 | $5,169,000 | 0.55% |
| RICE HALL JAMES & ASSOCIATES, LLC | 1,776,490 | $8,980,000 | 0.32% |
| FARALLON CAPITAL MANAGEMENT LLC | 7,350,000 | $37,154,000 | 0.28% |
| NEXPOINT ASSET MANAGEMENT, L.P. | 716,880 | $3,624,000 | 0.23% |
| J. Goldman & Co LP | 499,698 | $2,526,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,257,098 | $6,355,000 | 0.15% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $19,957,000 | 0.14% |
| EAGLE ASSET MANAGEMENT INC | 4,504,094 | $22,768,000 | 0.12% |
| Worth Venture Partners, LLC | 32,956 | $167,000 | 0.10% |